Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Regeneron Pharmaceuticals, Inc. (REGN : NSDQ)
 
 • Company Description   
Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Number of Employees: 11,851

 
 • Price / Volume Information   
Yesterday's Closing Price: $731.17 Daily Weekly Monthly
20 Day Moving Average: 507,904 shares
Shares Outstanding: 109.33 (millions)
Market Capitalization: $79,935.55 (millions)
Beta: 0.23
52 Week High: $837.55
52 Week Low: $538.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.01% -6.68%
12 Week -1.69% -8.74%
Year To Date 1.34% -7.82%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
777 OLD SAW MILL RIVER ROAD
-
TARRYTOWN,NY 10591
USA
ph: 914-847-7000
fax: 914-347-2113
invest@regeneron.com http://www.regeneron.com
 
 • General Corporate Information   
Officers
Leonard S. Schleifer - President; Chief Executive Officer
P. Roy Vagelos - Chair of the Board of Directors
George D. Yancopoulos - President; Chief Scientific Officer
Robert E. Landry - Executive Vice President; Finance and Chief Financ
Christopher R. Fenimore - Senior Vice President; Controller

Peer Information
Regeneron Pharmaceuticals, Inc. (CORR.)
Regeneron Pharmaceuticals, Inc. (RSPI)
Regeneron Pharmaceuticals, Inc. (CGXP)
Regeneron Pharmaceuticals, Inc. (BGEN)
Regeneron Pharmaceuticals, Inc. (GTBP)
Regeneron Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75886F107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/02/23
Share - Related Items
Shares Outstanding: 109.33
Most Recent Split Date: (:1)
Beta: 0.23
Market Capitalization: $79,935.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $8.78 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $34.76 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 9.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 21.04
Trailing 12 Months: 18.68
PEG Ratio: 2.34
Price Ratios
Price/Book: 3.40
Price/Cash Flow: 16.42
Price / Sales: 6.46
EPS Growth
vs. Year Ago Period: -26.54%
vs. Previous Quarter: -22.99%
Sales Growth
vs. Year Ago Period: 6.64%
vs. Previous Quarter: -7.39%
ROE
03/31/23 - 20.41
12/31/22 - 22.87
09/30/22 - 31.16
ROA
03/31/23 - 15.79
12/31/22 - 17.54
09/30/22 - 23.61
Current Ratio
03/31/23 - 5.45
12/31/22 - 5.06
09/30/22 - 5.36
Quick Ratio
03/31/23 - 4.67
12/31/22 - 4.29
09/30/22 - 4.52
Operating Margin
03/31/23 - 36.42
12/31/22 - 39.79
09/30/22 - 45.92
Net Margin
03/31/23 - 33.81
12/31/22 - 35.64
09/30/22 - 39.17
Pre-Tax Margin
03/31/23 - 37.64
12/31/22 - 39.92
09/30/22 - 44.04
Book Value
03/31/23 - 214.91
12/31/22 - 207.31
09/30/22 - 196.86
Inventory Turnover
03/31/23 - 0.68
12/31/22 - 0.69
09/30/22 - 0.93
Debt-to-Equity
03/31/23 - 0.11
12/31/22 - 0.12
09/30/22 - 0.13
Debt-to-Capital
03/31/23 - 10.31
12/31/22 - 10.65
09/30/22 - 11.19
 

Powered by Zacks Investment Research ©